Skip to main content
Journal cover image

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Publication ,  Journal Article
Singer, DE; Hellkamp, AS; Piccini, JP; Mahaffey, KW; Lokhnygina, Y; Pan, G; Halperin, JL; Becker, RC; Breithardt, G; Hankey, GJ; Hacke, W ...
Published in: J Am Heart Assoc
February 19, 2013

BACKGROUND: Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial. METHODS AND RESULTS: TTR (international normalized ratio [INR] 2.0 to 3.0) was determined using standard linear interpolation in patients randomized to warfarin in the ROCKET AF trial. Factors associated with TTR at the individual patient level (i-TTR) were determined via multivariable linear regression. Among 6983 patients taking warfarin, recruited from 45 countries grouped into 7 regions, the mean i-TTR was 55.2% (SD 21.3%) and the median i-TTR was 57.9% (interquartile range 43.0% to 70.6%). The mean time with INR <2 was 29.1% and the mean time with an INR >3 was 15.7%. While multiple clinical features were associated with i-TTR, dominant determinants were previous warfarin use (mean i-TTR of 61.1% for warfarin-experienced versus 47.4% in VKA-naïve patients) and geographic region where patients were managed (mean i-TTR varied from 64.1% to 35.9%). These effects persisted in multivariable analysis. Regions with the lowest i-TTRs had INR distributions shifted toward lower INR values and had longer inter-INR test intervals. CONCLUSIONS: Independent of patient clinical features, the regional location of medical care is a dominant determinant of variation in i-TTR in global studies of warfarin. Regional differences in mean i-TTR are heavily influenced by subtherapeutic INR values and are associated with reduced frequency of INR testing. CLINICAL TRIAL REGISTRATION: URL: ClinicalTrials.gov. Unique identifier: NCT00403767.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 19, 2013

Volume

2

Issue

1

Start / End Page

e000067

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Time Factors
  • Thiophenes
  • Stroke
  • South America
  • South Africa
  • Rivaroxaban
  • Residence Characteristics
  • Predictive Value of Tests
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., … ROCKET AF Investigators, . (2013). Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2(1), e000067. https://doi.org/10.1161/JAHA.112.000067
Singer, Daniel E., Anne S. Hellkamp, Jonathan P. Piccini, Kenneth W. Mahaffey, Yuliya Lokhnygina, Guohua Pan, Jonathan L. Halperin, et al. “Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.J Am Heart Assoc 2, no. 1 (February 19, 2013): e000067. https://doi.org/10.1161/JAHA.112.000067.
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013 Feb 19;2(1):e000067.
Singer, Daniel E., et al. “Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.J Am Heart Assoc, vol. 2, no. 1, Feb. 2013, p. e000067. Pubmed, doi:10.1161/JAHA.112.000067.
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KAA, ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013 Feb 19;2(1):e000067.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 19, 2013

Volume

2

Issue

1

Start / End Page

e000067

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Time Factors
  • Thiophenes
  • Stroke
  • South America
  • South Africa
  • Rivaroxaban
  • Residence Characteristics
  • Predictive Value of Tests